Engstrøm T, et al. - Previous animal models indicated that danegaptide may be able to reduce myocardial damage related to reperfusion immediately after reopening of the infarct-related artery in ST-segment elevation myocardial infarction (STEMI), so researchers attempted to determine the impact of danegaptide on myocardial salvage in patients with STEMI. In this clinical proof-of-concept study, myocardial salvage as assessed by cardiac MRI after 3 months was the primary outcome. Ultimately, no improvement in myocardial salvage was noted as a result of administering danegaptide to patients with STEMI.